#United States #Chicago #Bexion Pharmaceuticals #BXQ-350 #AACR 2025

Bexion Pharmaceuticals to Present at AACR Annual Meeting 2025

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has announced their participation at the highly anticipated American Association for Cancer Research (AACR) Annual Meeting 2025 set to take place from April 25 to April 30 in Chicago, Illinois. With a focus on pioneering treatments, Bexion has made significant strides in developing a novel class of biologic therapy aimed at combatting solid tumor cancers as well as addressing chemotherapy-induced peripheral neuropathy (CIPN).

The company will present two insightful poster presentations during the event, marking a significant opportunity to share their latest research findings with the global scientific community.

Details of the Presentations

First Poster Presentation

• - Abstract Title: Development of an in-house methodology to analyze large clinical cancer biomarkers datasets
• - Abstract Number: 1105
• - Poster Board Number: 12
• - Session Title: Tumor Subtypes and Biomarker Discovery
• - Session Date: Sunday, April 27, 2025
• - Session Time: 2:00 PM - 5:00 PM
• - Presenter: Dr. Tariq Arshad

This first presentation will highlight the innovative methodologies developed by Bexion for analyzing extensive datasets related to clinical cancer biomarkers. Insights gained from this research are expected to deepen the understanding of tumor subtypes and enhance biomarker discovery.

Second Poster Presentation

• - Abstract Title: Sphingolipid modulating compounds BXQ-350 and desipramine display synergy in reducing viability across multiple cancer cell types in vitro
• - Abstract Number: 5439
• - Poster Board Number: 17
• - Session Title: Therapeutic Targets and Mitochondrial Function
• - Session Date: Tuesday, April 29, 2025
• - Session Time: 2:00 PM - 5:00 PM
• - Presenter: Dr. Tariq Arshad

The second poster presentation will focus on Bexion's lead drug candidate, BXQ-350, which has demonstrated promising results in synergistically reducing cancer cell viability in vitro when combined with desipramine. This finding is significant as it could lead to new therapeutic strategies for various solid tumors.

About AACR

The American Association for Cancer Research is the foremost organization dedicated to the fight against cancer, providing a platform for groundbreaking cancer research and fostering collaboration among scientists and clinicians worldwide. The Annual Meeting serves as a convergence point for the latest discoveries related to cancer biology, prevention, and treatment, making it a critical event for healthcare professionals and researchers in the field.

About Bexion Pharmaceuticals

Bexion Pharmaceuticals is at the forefront of developing a new generation of biologic therapies designed to treat solid tumor cancers and CIPN. Their lead candidate, BXQ-350, has demonstrated a solid safety profile in multiple Phase 1 clinical trials while also showing activity across various solid tumor types. Bexion's commitment to advancing its portfolio positions them as a key player in the ongoing battle against cancer.

In closing, Bexion Pharmaceuticals' presentations at the AACR Annual Meeting 2025 represent not only their commitment to innovation in cancer treatment but also their willingness to share vital research insights that could impact the future of oncology. The scientific community eagerly awaits these presentations as they could provide new avenues for therapeutic development and patient care.

Contact Information

For further information about the presentations or Bexion Pharmaceuticals, interested parties can reach out to:

• - Investor Contact: William Windham, Solebury Strategic Communications, 646-378-2946
• - Media Contact: Joyce LaViscount, Bexion Pharmaceuticals, 859-446-7386

As Bexion continues to push the boundaries of cancer research, their presence at AACR 2025 is not just an opportunity to share their findings but a chance to pave the way for future breakthroughs in oncology.